M&A / Deals Merck Chopped $1B Off Terns’ Offer After Seeing Updated Leukemia Data BioSpaceAnother bidder, which remains unidentified, dropped out of the bidding process.M&A / DealsHematologyRead full story pharminent April 8, 2026 (Last updated: April 8, 2026) BioSpace Another bidder, which remains unidentified, dropped out of the bidding process. M&A / DealsHematologyRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: List Price Reductions Will Deflate the Gross-to-Net Bubble-and Threaten Pharmacy and 340B Profits from IRA-Negotiated Drugs (rerun)Next: Insmed Scraps Skin Plans for Lung Disease Drug as Competitors Make Headway Related Stories M&A / Deals J&J ventures further into in vivo CAR-T space with Sail partnership, potential buyout pharminent July 31, 2026 M&A / Deals Eisai and CORE Biomedicine agree on global licence for oncology pipeline pharminent July 29, 2026 M&A / Deals Argenx signs agreement to buy Forte Biosciences for $2.2bn pharminent July 28, 2026
